Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis

被引:11
作者
Honda, N. [1 ]
Jinnin, M. [1 ]
Kajihara, I. [1 ]
Makino, T. [1 ]
Fukushima, S. [1 ]
Ihn, H. [1 ]
机构
[1] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan
关键词
angiogenesis; collagen; cytokine; immunohistochemistry; ulcer; SCLERODERMA SPECTRUM DISORDERS; GENERAL-POPULATION; ANGIOGENESIS; VEGF; CLASSIFICATION; PATHOGENESIS; EXPRESSION; RECEPTORS; PROTEINS; DISEASE;
D O I
10.1111/j.1365-2133.2010.09853.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P>Background Vascular abnormalities are one of the primary pathological components of systemic sclerosis (SSc). However, it has not been determined if there are also abnormalities in the formation of lymphatic vessels in SSc. Objective To evaluate lymphangiogenic activity in SSc skin. Methods The numbers of D2-40-positive lymphatic vessels in skin specimens from healthy control subjects and patients with SSc were counted and compared. Quantitative real-time polymerase chain reaction (PCR) was performed to determine mRNA levels of vascular endothelial growth factor (VEGF)-D and Flt-4 (fms-related tyrosine kinase 4, VEGFR-3, one of the receptors for VEGF-D) in the skin. Serum VEGF-D levels were measured with specific enzyme-linked immunosorbent assays. Results The number of lymphatic vessels in patients with SSc was significantly decreased compared with healthy control subjects. Mean relative transcript levels of FIGF (VEGF-D) and FLT4 (Flt-4) in skin tissue from patients with SSc were significantly increased compared with healthy control subjects. By the analysis of the association between serum VEGF-D levels and the clinical or laboratory features, we found that patients with SSc with higher serum VEGF-D levels more frequently have skin ulcers than those with normal VEGF-D levels. Conclusions A systemic increase of VEGF-D, as well as local overexpression of FIGF and FLT4, may be the cause of disturbed lymphangiogenesis in SSc skin and play a role in the pathogenesis of SSc. We showed the possibility that regulation of VEGF-D/Flt-4 signalling could lead to new treatment of skin ulcers in SSc by controlling the formation of lymphatic vessels.
引用
收藏
页码:776 / 780
页数:5
相关论文
共 19 条
[1]   The vascular endothelial growth factor family; proteins which guide the development of the vasculature [J].
Achen, MG ;
Stacker, SA .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 1998, 79 (05) :255-265
[2]  
Brekken RA, 2000, CANCER RES, V60, P5117
[3]   ABNORMALITIES OF HUMAN SUPERFICIAL CUTANEOUS LYMPHATICS ASSOCIATED WITH STASIS ULCERS, LYMPHEDEMA, SCARS AND CUTANEOUS AUTOGRAFTS [J].
BUTCHER, HR ;
HOOVER, AL .
ANNALS OF SURGERY, 1955, 142 (04) :633-653
[4]   High circulating levels of VEGF-C suggest abnormal lymphangiogenesis in systemic sclerosis [J].
Chitale, S. ;
Al-Mowallad, A. F. ;
Wang, Q. ;
Kumar, S. ;
Herrick, A. .
RHEUMATOLOGY, 2008, 47 (11) :1727-1728
[5]   The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis [J].
Davies, CA ;
Jeziorska, M ;
Freemont, AJ ;
Herrick, AL .
HUMAN PATHOLOGY, 2006, 37 (02) :190-197
[6]   Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis [J].
Distler, O ;
Distler, JHW ;
Scheid, A ;
Acker, T ;
Hirth, A ;
Rethage, J ;
Michel, BA ;
Gay, RE ;
Müller-Ladner, U ;
Matucci-Cerinic, M ;
Plate, KH ;
Gassmann, M ;
Gay, S .
CIRCULATION RESEARCH, 2004, 95 (01) :109-116
[7]  
Ferrara N, 2005, EXP SUPPL, V94, P209
[8]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[9]   CLINICAL-EVALUATION OF SCLERODERMA SPECTRUM DISORDERS USING A POINTS SYSTEM [J].
IHN, H ;
TAMAKI, T ;
SOMA, Y ;
TSUCHIDA, T ;
ISHIBASHI, Y ;
TAKEHARA, K .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1992, 284 (07) :391-395
[10]  
Ihn H, 1996, CLIN EXP IMMUNOL, V37, P1188